Figure 4From: Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence Probability of progression-free survival (a) and androgen deprivation therapy-free survival (b) stratified according to PSA doubling time ≤ 3mo compared to > 3 mo. Back to article page